LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 160 participants.

Also called NCT07645300

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07645300
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07645300. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-01 (anticipated); primary completion 2032-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial
Acronym
LODESTAR
Condition
Hypertension Treated With Antihypertensive Drugs
Condition
Chronic Kidney Disease, 3B and 4
Intervention (Drug)
phase 2A Chlorthalidone
Intervention (Drug)
phase 2A Spironolactone
Intervention (Drug)
phase 2A Chlorthalidone + Spironolactone
Intervention (Drug)
phase 2B Chlorthalidone LD + Spironolactone LD
Lead sponsor
VA Office of Research and Development (class: US federal agency)
Collaborator
Michael E. DeBakey VA Medical Center (class: US federal agency)
Collaborator
VA Salt Lake City Health Care System (class: US federal agency)

Record details

Record id
cardio:ct-nct07645300
Content hash
a722f9c02b502df51e143bbe7f4a51fb2c8c3da4838f67c3215608d1ef2e74db